Aeterna Zentaris to Make Oral Presentation on Targeted Inhibitors for PI3K and Erk at Cancer Conference in Berlin
March 15 2011 - 8:30AM
PR Newswire (US)
QUÉBEC CITY, March 15 /PRNewswire/
- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the
"Company") today announced that its Senior Director, Head of
Preclinical Development, Michael
Teifel, Ph.D., will present preclinical results for PI3K/Erk
inhibitors AEZS-129, AEZS-131, and AEZS-132, which support further
evaluation as potential anticancer compounds. This oral
presentation will be made during the Informa Life Sciences Protein
Kinases Congress to be held March 22-23,
2011 in Berlin,
Germany.
Title: |
"Finding novel Kinases targets in oncology at Aeterna
Zentaris - Development of inhibitors targeting the MAPK and
PI3K pathways" |
Presenter: |
Michael Teifel, Ph.D., Senior
Director, Head of Preclinical Development, Aeterna Zentaris |
Date: |
Tuesday, March 22, 2011 at 9:30 a.m.
(local time) |
Location: |
Maritim ProArte Hotel, Berlin,
Germany. |
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development
company currently investigating potential treatments for various
cancers including colorectal, ovarian, endometrial cancer and
multiple myeloma. The Company's innovative approach of
"personalized medicine" means tailoring treatments to a patient's
specific condition and to unmet medical needs. Aeterna Zentaris'
deep pipeline is drawn from its proprietary discovery unit
providing the Company with constant and long-term access to
state-of-the-art therapeutic options. For more information please
visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.
Copyright h 15 PR Newswire
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024